Target intelligence / Profile preview

Bacterial ribosome 30S subunit A-site (30S A-site)

Target
30S A-site
Molecular classification
Ribonucleoprotein complex, Other
01

Overview

The bacterial ribosome 30S subunit A-site, also known as the decoding site, is a critical functional region within the small ribosomal subunit of prokaryotes responsible for ensuring the fidelity of protein synthesis (Wikipedia, 2024). It is primarily composed of the 16S ribosomal RNA (rRNA), where highly conserved adenine residues (A1492 and A1493) monitor the base-pairing between the mRNA codon and the tRNA anticodon (Carter et al., Nature, 2000). This site is the primary target for several major classes of antibiotics, including aminoglycosides and tetracyclines (Patsnap, 2024). Aminoglycosides bind to the A-site and induce a conformational change that stabilizes the binding of near-cognate tRNAs, leading to mRNA misreading and the production of erroneous, toxic proteins (NIH, 2018). Tetracyclines, in contrast, bind to the A-site to sterically block the entry of aminoacyl-tRNAs, thereby halting the elongation phase of translation (NIH, 2018). Due to the structural similarity between bacterial and human mitochondrial ribosomes, drugs targeting this site can cause significant safety concerns, such as ototoxicity and nephrotoxicity (Gosset.ai, 2026).

Other names
Decoding siteAminoacyl-tRNA binding site30S decoding center16S rRNA A-siteRibosomal A-site
02

Mechanism of action

Aminoglycosides bind to the 16S rRNA A-site, inducing a conformational change in residues A1492 and A1493 that stabilizes near-cognate tRNA binding, leading to mRNA misreading and the production of faulty proteins (Carter et al., Nature, 2000). Tetracyclines bind to the A-site to sterically block the entry of aminoacyl-tRNA, thereby inhibiting the elongation phase of protein synthesis (NIH, 2018).

03

Biological functions

Protein synthesismRNA decodingTranslational fidelityOther
04

Disease associations

Infection
05

Safety considerations

OtotoxicityNephrotoxicityNeuromuscular blockadeMitochondrial ribosome inhibitionDevelopment of multi-drug resistance
06

Interacting drugs

Gentamicin

11 more in the full profile.

07

Biomarkers

16S rRNA methyltransferase (e.g., ArmA, RmtB)16S rRNA mutations (e.g., A1408G)Ribosomal protein S12 mutationsMinimum Inhibitory Concentration (MIC)

Beyond the preview

Go deeper on Bacterial ribosome 30S subunit A-site (30S A-site).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial ribosome 30S subunit A-site (30S A-site).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call